MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Journal of Clinical Oncology
Topic
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

9,514 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
9,514 works in the cohort · of 4,299,418page 62 of 191

Labels cover 106 of 9,514 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 9,514 of 9,514 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affno abstractunlabeled
Delay of Radiation Therapy and Outcomes of Breast Cancer
Nicole Hébert‐Croteau, Carolyn Freeman, Jean Latreille, Jacques Brisson
2004· letter· en· Journal of Clinical Oncology· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
6
citations
fundno affunlabeled
Trastuzumab and pertuzumab in combination with eribulin mesylate or a taxane as first-line chemotherapeutic treatment for HER2-positive, locally advanced or metastatic breast cancer: Results of a multicenter, randomized, non-inferiority phase 3 trial in Japan (JBCRG-M06/EMERALD).
Toshinari Yamashita, Shigehira Saji, Toshimi Takano, Yoichi Naito, Michiko Tsuneizumi, Akiyo Yoshimura +14 more
2024· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
6
citations
affunlabeled
Phase II study of PX-866 in recurrent glioblastoma.
Marshall Pitz, Elizabeth A. Eisenhauer, Mary MacNeil, Brian Thiessen, David Macdonald, Jacob C. Easaw +8 more
2013· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
6
citations
affunlabeled
Health-related quality of life (HRQoL) and pain outcomes for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who received abiraterone (abi) and olaparib (ola) versus (vs) abi and placebo (pbo) in the phase III PROpel trial.
Antoine Thiery-Vuillemin, Fred Saad, Andrew J. Armstrong, Mototsugu Oya, Karina Vianna, Mustafa Özgüroğlu +14 more
2023· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
6
citations
affunlabeled
Final analysis of the phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with chemotherapy refractory, <i>K-RAS </i>wild-type (WT), metastatic colorectal carcinoma (mCRC): The NCIC Clinical Trials Group and AGITG CO.20 trial.
Lillian L. Siu, Jeremy Shapiro, Derek J. Jonker, Christos S. Karapetis, John Zalcberg, John Simes +14 more
2012· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
6
citations
affunlabeled
Analysis of metabolic response (MR) by positron emission tomography (PET) compared with tumor response by computed tomography (CT) from MPACT, a phase III trial comparing <i>nab</i>-paclitaxel (<i>nab</i>-P) plus gemcitabine (G) versus G alone for patients (pts) with metastatic adenocarcinoma of the pancreas.
Ramesh K. Ramanathan, Daniel D. Von Hoff, Malcolm J. Moore, Luís Teixeira, Salvatore Siena, Josep Tabernero +3 more
2014· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
6
citations

How this was built: Screen · Findings · About